Prognostication in myeloproliferative neoplasms, including mutational abnormalities.

Area of Science:

• Hematology
• Oncology
• Molecular Biology

Background:

• Myeloproliferative neoplasms (MPNs) are a group of blood cancers characterized by the overproduction of myeloid cells.
• Advances in understanding MPN molecular features are crucial for refining prognostic assessments.
• Existing prognostic models rely on clinical, laboratory, and cytogenetic data.

Purpose of the Study:

• To integrate molecular data with clinical information to enhance prognostic models for MPNs.
• To evaluate the effectiveness of mutation-enhanced prognostic systems in predicting patient outcomes.
• To develop tailored prognostic tools for different MPN subtypes, including secondary myelofibrosis.

Main Methods:

• Review and synthesis of existing prognostic models for MPNs.
• Incorporation of molecular findings into established prognostic frameworks, such as Mutation-Enhanced International Prognostic Systems (MIPSS).
• Development of specific models for myelofibrosis secondary to polycythemia vera (PV) and essential thrombocythemia (ET).

Main Results:

• Mutation-enhanced international prognostic systems (MIPSS) have improved prognostic accuracy for polycythemia vera (PV) and essential thrombocythemia (ET).
• MIPSS70 and its revisions (MIPSS70+, MIPSS70+ version 2.0) demonstrated effectiveness in predicting overall survival (OS) in overt primary myelofibrosis (PMF).
• A dedicated prognostic model for myelofibrosis secondary to PV and ET was developed due to distinct disease characteristics.

Conclusions:

• Molecular-inspired prognostic models are poised to significantly enhance prognostic power in the molecular era of MPN management.
• These advanced models are expected to facilitate the development of personalized treatment strategies.
• Predicting survival outcomes with these models can guide therapeutic decisions, including drug selection and allogeneic stem cell transplantation, ultimately aiming to improve overall survival in MPN patients.